Catalyst Wire Dossier Catalyst Wire Dossier

MR901

talaporfin sodium · Light Sciences Oncology
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MR901, covering 2018-08-08 to 2018-08-08. Get the full timeline:

Most recent: Clinical Trial Update: A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia [Phase 2]

See pricing